Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 12 patents granted in the last 365 days
Foghorn Therapeutics Inc. is navigating 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are handled by 2 distinct examiners across the same count of distinct art units. This distribution shows that each pending matter is being reviewed by a different individual in a different specialized unit. For a practitioner, this suggests that the company's patent applications are being evaluated for distinct technical merits by separate groups rather than being clustered under a single authority.
INAM, SAHAR is the busiest examiner for this portfolio, with 1 pending office action under review. Since there are multiple pending office actions in total, and multiple distinct examiners, the busiest examiner is responsible for 1 action. The presence of distinct art units for the actions suggests that the company's intellectual property spans different sub-specialties within the biotechnology sector. This requires a prosecution strategy that accounts for the specific standards of different art units and the individual approaches of the assigned examiners to ensure consistent progress across the portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| INAM, SAHAR | 1 | 100.0% | +0.0% |
| BAUER, NICOLA MARIA | 1 | 58.3% | +50.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18253541 | COMPOUNDS AND USES THEREOF | BAUER, NICOLA MARIA | 21d |
| 18292582 | METHODS OF TREATING CANCER | INAM, SAHAR | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18253541 | COMPOUNDS AND USES THEREOF | BAUER, NICOLA MARIA | 21d |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18292582 | METHODS OF TREATING CANCER | INAM, SAHAR | 1622 | §102§103 | Non-Final OA | — | Pending | Jan 26, 2024 |
| 18253541 | COMPOUNDS AND USES THEREOF | BAUER, NICOLA MARIA | 1621 | §103§112 | Final Rejection | 21d | Pending | May 18, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial